Clinical trial NCT03456323: Post-ICU Palliative Care Intervention (PIPCI) Trial
Official title: Post-ICU Palliative Care Consultation Intervention Pilot Trial in Older Survivors of Acute Respiratory Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Critical Illness
Frailty
Palliative Care
Keywords: Critical Illness
Frailty
Palliative Care
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2018-03-07
Enrollment: 66
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Older survivors of acute respiratory failure and their surrogates (i.e., patient-surrogate pairs, n = 80 participants total) will be randomized to an inpatient palliative care consultation versus usual care in a 1:1 ratio (i.e. 20 patient-surrogate pairs (40 participants total) in each study arm) once enrolled patients are registered to be transferred from the ICU to the general ward.
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a single center, pilot, randomized, single-blind, usual care controlled, pragmatic clinical trial of a post-ICU palliative care consultation intervention in older (age ≥50 years) survivors of acute respiratory failure.

Aim 1: To conduct a pilot post-ICU palliative care consultation intervention trial among frail older ICU survivors and their surrogates. Hypothesis:The Investigators can achieve an adequate enrollment rate, protocol adherence, and intervention fidelity.

Aim 2: To estimate effect sizes and variability for changes in symptoms at hospital discharge and 1 month, and to estimate hospice referral rates and acute-care readmission rates at 1 and 3 months. Hypothesis: Effect sizes and feasibility data will inform and support future post-ICU palliative care studies focused on improving ICU survivorship.

Exploratory Aim. To assess the use of methylphenidate that is recommended and dosed by the palliative care physician for the treatment of moderate-to-severe fatigue. Hypothesis: (1) Not all patients with moderate-to-severe fatigue will be recommended for methylphenidate therapy. (2) Patients prescribed methylphenidate for treatment of moderate-to-severe fatigue after critical illness will adhere to methylphenidate therapy.

Detailed description: There is an urgent need for research to improve outcomes for the rapidly growing population of older survivors of critical illness. Most adults, including older adults, survive critical illness. While recovery with minimal sequelae occurs, a substantial proportion of survivors are left with physical disability and cognitive impairment, have an increased risk of death, and incur high health care costs after hospital discharge. In prior work the Investigators have shown that about 75% of older survivors of respiratory failure are phenotypically frail and that these frail ICU survivors have a high burden of uncontrolled symptoms at hospital discharge and 1-month later. Moderate to severe post-ICU fatigue is the most prevalent symptom and may interfere with functional recovery.

This study is designed to determine whether consultation with a palliative care team may help alleviate any physical symptoms or psychological distress that the patients and their caregivers (surrogates) have coming out of the ICU.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 50 years.
* Acute respiratory failure requiring invasive mechanical ventilation, non-invasive mechanical ventilation (continuous or bi-level positive pressure), or high flow nasal cannula for greater than 24 hours in a Columbia University Medical Center medical or surgical ICU.

Exclusion Criteria:

* Hospital discharge directly from ICU.
* Already received palliative care consultation during the hospitalization.
* Planned discharge to hospice or home hospice. These patients do not need further palliative care consultation since they have already decided on prioritizing palliative care over life-sustaining treatment.
* Respiratory failure due to neurologic diagnosis (intracranial hemorrhage, stroke, or coma). These patients are unlikely to be able to participate in any frailty measurements, and may have difficulty with communicating their symptom burden.
* Pre-existing neurologic disease or stroke with motor deficits. Older adults with motor diseases (e.g Parkinson's disease) will be excluded from frailty measurements because they could present with frailty characteristics from a single disease. This criterion was used to exclude subjects in the original Cardiovascular Health Study from which the Fried frailty phenotype was first assessed.
* Psychiatric history of Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia.
* Current Alcoholism or drug abuse.
* Not English or Spanish speaking. Many surveys are not validated in other languages besides English or Spanish. Obtaining interpreters in other languages for palliative care assessments and intervention can be challenging. We expect \< 3% of all potentially eligible patients/surrogates to not have English or Spanish speaking ability.
* No healthcare proxy or surrogate also consenting to participate.
* Expected to be discharged to a location \>20 miles from Columbia University Medical Center. This discharge radius will make in-person 1-month follow-up feasible.
* Status post heart, lung, or liver transplantation. These patients are not representative of the larger population of older adult survivors of acute respiratory failure.

Primary outcomes:
measure: Annual enrollment rate
timeFrame: 1 year
measure: Adherence to the palliative care consultation intervention
timeFrame: From date of Randomization until the date of hospital discharge or 28 days later.
measure: Crossover from usual care to post-ICU palliative care
timeFrame: From date of Randomization until the date of hospital discharge or 28 days later.
measure: Fidelity of the palliative care intervention
timeFrame: From date of Randomization until the date of hospital discharge or 28 days later.
Secondary outcomes:
measure: Change in Edmonton Symptom Assessment System (ESAS) scores
timeFrame: Pre-randomization baseline until the date of hospital discharge or 28 days later, and 1-month follow-up after hospital discharge.
measure: Change in Hospital Anxiety and Depression Scores (HADS) for surrogates
timeFrame: Pre-randomization baseline until the date of hospital discharge or 28 days later, and 1-month follow-up after hospital discharge.
Other outcomes:
measure: Number of patients with moderate-to-severe fatigue who are recommended for and receive methylphenidate treatment.
timeFrame: Randomization until 1-month follow-up after hospital discharge.
measure: New limitation of life-sustaining therapy
timeFrame: Day of hospital discharge until 3-month follow-up after hospital discharge.
measure: Enrollment in Hospice
timeFrame: Day of hospital discharge until 3-month follow-up after hospital discharge.
measure: Acute-care readmissions
timeFrame: Day of hospital discharge until 3-month follow-up after hospital discharge.
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Matthew R Baldwin, MD, MS
role: PRINCIPAL_INVESTIGATOR
References: